All In Biotech

Drug Trial Radar · NCT01214421

Tolvaptan Extension Study in Participants With ADPKD

Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Last checked: Nov 20, 2026Latest source record: Oct 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,083

Actual

Start

May 26, 2010

Primary completion

Feb 29, 2016

Study completion Feb 29, 2016

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • TolvaptanDrug

    Tablets of 15 or 30 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)Time frame: Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)

Locations

97 sites in 13 countries. Site status is shown where the registry gives one.

  • Otsuka Investigational Site

    Mobile, Alabama

  • Otsuka Investigational Site

    Peoria, Arizona

  • Otsuka Investigational Site

    Tempe, Arizona

  • Otsuka Investigational Site

    Los Angeles, California

  • Otsuka Investigational Site

    Palo Alto, California

  • Otsuka Investigational Site

    San Diego, California

  • Otsuka Investigational Site

    Aurora, Colorado

  • Otsuka Investigational Site

    New Haven, Connecticut

  • Otsuka Investigational Site

    Jacksonville, Florida

  • Otsuka Investigational Site

    Port Charlotte, Florida

  • Otsuka Investigational Site

    Atlanta, Georgia

  • Otsuka Investigational Site

    Augusta, Georgia

  • Otsuka Investigational Site

    Chicago, Illinois

  • Otsuka Investigational Site

    Kansas City, Kansas

  • Otsuka Investigational Site

    Baton Rouge, Louisiana

  • Otsuka Investigational Site

    Baltimore, Maryland

  • Otsuka Investigational Site

    Rockville, Maryland

  • Otsuka Investigational Site

    Boston, Massachusetts

  • Otsuka Investigational Site

    Detroit, Michigan

  • Otsuka Investigational Site

    Minneapolis, Minnesota

  • Otsuka Investigational Site

    Rochester, Minnesota

  • Otsuka Investigational Site

    Voorhees Township, New Jersey

  • Otsuka Investigational Site

    Buffalo, New York

  • Otsuka Investigational Site

    Hawthorne, New York

  • Otsuka Investigational Site

    New York, New York

  • Otsuka Investigational Site

    New York, New York

  • Otsuka Investigational Site

    Chapel Hill, North Carolina

  • Otsuka Investigational Site

    Cincinnati, Ohio

  • Otsuka Investigational Site

    Cleveland, Ohio

  • Otsuka Investigational Site

    Portland, Oregon

  • Otsuka Investigational Site

    Bethlehem, Pennsylvania

  • Otsuka Investigational Site

    Philadelphia, Pennsylvania

  • Otsuka Investigational Site

    Anderson, South Carolina

  • Otsuka Investigational Site

    Nashville, Tennessee

  • Otsuka Investigational Site

    Nashville, Tennessee

  • Otsuka Investigational Site

    Arlington, Texas

  • Otsuka Investigational Site

    McAllen, Texas

  • Otsuka Investigational Site

    Charlottesville, Virginia

  • Otsuka Investigational Site

    Buenos Aires, Argentina

  • Otsuka Investigational Site

    Córdoba, Argentina

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.